Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib
Pei N. Ding(Liverpool Hospital), Victoria Bray, Prunella Blinman(The University of Sydney), Nicole Caixeiro(Camden and Campbelltown Hospitals), Tara L. Roberts(Camden and Campbelltown Hospitals), Helen Westman(Northern Cancer Institute), Malinda Itchins(The University of Sydney), Chee Khoon Lee(The University of Sydney), Wei Chua(Liverpool Hospital), José Luis Leal(Peter MacCallum Cancer Centre), Stephen Clarke(The University of Sydney), Steven Kao(Chris O’Brien Lifehouse), Bo Gao(Blacktown & Mount Druitt Hospital), Therese M. Becker(Liverpool Hospital), Paul de Souza(St. George Hospital)
Cited by 11
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
|Journal of Thoracic Oncology|2016|842